Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Stopped early · Phase 2

Conditions studied: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia

In brief

The purpose of this study is to determine if haplotype-mismatched HSCT is associated with an improvement in treatment-related mortality (TRM) rate at 6 months.

Key facts

Study ID

NCT00593554

Run by

Sherif S. Farag

People needed

9

Starts

2007-08-07

Expected to finish

2017-07-28

Last updated by the study team

2018-04-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically documented AML, ALL, MDS, CML, Acute myeloid leukemia (AML) with one or more of the following criteria
• CR 1 with poor risk features
• CR 2, or higher order CR
• Acute lymphoblastic leukemia (ALL) with one of the following criteria
• CR 1 with poor risk features
• CR 2, or higher order CR
• Myelodysplasia, RAEB I
• Donor has been identified
• Age ≤ 65 years.
• Performance Status 0-1.

You may not qualify if…

• Patients relapsing <6 months after autologous SCT are not eligible.
• Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.
• Non-pregnant and non-nursing

Where it is running

• Indiana University Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.